CYCCP News and Press, Cyclacel Pharmaceuticals Inc. 6% Convertible Preferred Stock From 07/07/21

BERKELEY HEIGHTS, N.J., July 07, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it will participate in the Lade...

Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2021 Earnings Conference Call May 12, 2021, 04:30 PM ET Company Participants Spiro Rombotis - President and CEO Paul McBarron - EVP, Finance and COO Dr. Mark Kirschbaum - SVP and CMO Conference Call Participants Jonathan Aschoff - ROTH Capital Kevin De...

- Announces IND Authorization by FDA for Fadraciclib, a CDK2/9 Inhibitor, in Solid Tumors - - Recent Publication Reported that Overactive KRAS Mutants are Impeded by CDK9 Inhibition - - Following Recent Financing, Cash Runway Extended to Early 2023 - - Conf...

BERKELEY HEIGHTS, N.J., May 05, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce first quarter financial results an...

The following slide deck was published by Cyclacel Pharmaceuticals, Inc. in conjunction with this event. For further details see: Cyclacel Pharmaceuticals (CYCC) Presents At 33rd Annual Roth Virtual Conference - Slideshow

BERKELEY HEIGHTS, N.J., March 16, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the closing of its previously ...

BERKELEY HEIGHTS, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that the Company will present at th...

BERKELEY HEIGHTS, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of an underwritten...

BERKELEY HEIGHTS, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it intends to offer share...

The following slide deck was published by Cyclacel Pharmaceuticals, Inc. in conjunction with this event. For further details see: Cyclacel Pharmaceuticals (CYCC) Investor Presentation - Slideshow